TrialBMC infectious diseases2025

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial).

Karen Brorup Heje et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.